ROBERT NORDMAN: Open Payments
NPI 1891783338 · AUBURN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,097 in 43 payments from 12 companies in 2025. Trend: 2023 $2,178 · 2024 $876 · 2025 $1,097
Food & beverage: $1,097
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $238 |
| Teva Pharmaceuticals USA, Inc. | 6 | $163 |
| Neurocrine BioSciences, Inc. | 7 | $159 |
| Otsuka America Pharmaceutical, Inc. | 4 | $114 |
| Almatica Pharma LLC | 4 | $84 |
| Axsome Therapeutics, Inc. | 3 | $83 |
| E.R. Squibb & Sons, L.L.C. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Sage Therapeutics, LLC | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $33 |
Products named: ARISTADA, AUSTEDO XR, INGREZZA, REXULTI, LOREEV XR, Auvelity, COBENFY, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
